Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib With Pembrolizumab and Cetuximab in R/M HNSCC
NCT06912087Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in squamous cell carcinoma of the head and neck (HNSCC) (4 arms), sponsored by University of Chicago. Primary endpoints: Maximally Tolerated Dose at 28 days and Recommended Phase II Dose. Started Sep 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT06912087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06912087.